Page 2 - சீன சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021 -Results from the MARCH trial showed an ORR of 33.3% in triple-class-exposed RRMM patients with the Sd regimen, and 44.4% in patients who previously received CAR-T therapies- -Selinexor is currently the only commercially available XPO1 inhibitor- News provided by Share this article Share this article SHANGHAI and HONG KONG, June 3, 2021 /PRNewswire/ Antengene Corporation Limited ( Antengene , SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, announced that the results from the Phase II MARCH trial of selinexor plus low dose dexamethasone (the Sd regimen) for the treatment of Chinese patients with relapsed or refractory multiple myeloma (RRMM) are published at the 2021 American Society o

United statesAsia pacificAntengene corporationAmerican society of clinical oncologyEuropean hematology associationDrug administrationPrnewswire antengene corporation limitedAntengene corporation limitedVirtual congressNational comprehensive cancer networkChinese society of clinical oncologyCorporation limitedClinical oncologyAnnual meetingHematology associationChinese society